Empagliflozin: A Hospital Formulary Essential?

Empagliflozin is a medication used to treat type 2 diabetes and reduce the risk of kidney disease and heart failure in certain adults. It belongs to a class of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by lowering blood sugar levels through increased glucose excretion in urine. The drug is typically taken orally as a tablet once daily and can be taken with or without food. While empagliflozin can help manage diabetes and improve overall health when combined with lifestyle changes, it is not a cure. Patients are advised to continue taking it as directed by their doctor and to carry a diabetic identification bracelet for emergency treatment. Given its benefits in managing diabetes and associated complications, the question arises as to whether empagliflozin should be added to hospital formularies to improve patient access and outcomes.

Explore related products

Llewellyn's Complete Formulary of Magical Oils: Over 1200 Recipes, Potions & Tinctures for Everyday Use

$23.54 $29.99

Materia Medica and Formulary: An Herbal Studies Notebook and Journal for Herbalists of all Ages | 8.5 x 11 Large Size with 150 Pages

$12.95

The medical formulary... By Henry Beasley. With additions from the 6th London ed.

$32.99

The medical formulary By Henry Beasley. With additions from the 6th London ed. 1856 [Leather Bound]

$23.99

Jardiance

$10 $758.1

Synjardy

$18 $380.4

Empagliflozin's effectiveness in treating type 2 diabetes

Empagliflozin is a medication used in the treatment of type 2 diabetes mellitus. It belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by reducing the reabsorption of glucose in the kidneys and increasing its excretion in urine, thereby lowering blood sugar levels. This mechanism is particularly relevant for patients with type 2 diabetes, as they often exhibit increased expression of SGLT2, resulting in higher glucose reabsorption and elevated blood sugar levels.

Empagliflozin is usually taken as a tablet once daily, preferably at a consistent time, and can be taken with or without food. It is often prescribed in conjunction with other medications for chronic kidney disease or heart failure, as it helps to alleviate symptoms associated with these conditions by reducing the workload on the heart and slowing the progression of kidney disease.

The drug has been shown to be effective in reducing hyperglycemia in patients with type 2 diabetes, including those with stage 2 or 3a chronic kidney disease. It is also associated with weight loss and a reduced risk of cardiovascular events and mortality in patients with type 2 diabetes who are at high cardiovascular risk. In addition, empagliflozin may be particularly beneficial for patients with obesity or those at risk of weight gain.

While empagliflozin is generally safe for long-term use, it is important for patients to be aware of potential side effects and interactions with other medications or supplements. Alcohol consumption, for example, can increase the risk of low blood sugar levels, and certain pre-existing conditions or medical histories may impact the suitability of empagliflozin as a treatment.

Explore related products

Synjardy Xr

$30 $756.9

Trijardy Xr

$12 $378.6

Effect of Empagliflozin and Colesevelam on Diabetic Dyslipidemia: Effect of Empagliflozin and its combination with Colesevelam on experimentally induced diabetic dyslipidemia animals

$46

Efecto de Empagliflozin y Colesevelam en la dislipidemia diabética: Efecto de Empagliflozin y su combinación con Colesevelam en animales con ... inducida experimentalmente (Spanish Edition)

$47

Effetto di Empagliflozin e Colesevelam sulla dislipidemia diabetica: Effetto di Empagliflozin e della sua combinazione con Colesevelam su animali con ... indotta sperimentalmente (Italian Edition)

$47

EFFETTO DI EMPAGLIFLOZIN E METFORMINA NEI RATTI DIABETICI (Italian Edition)

$62.15

Its use as an add-on medication for heart failure

Empagliflozin is a medication that belongs to a class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily used to lower blood sugar levels in people with diabetes, particularly type 2 diabetes. By inhibiting SGLT2, empagliflozin causes the kidneys to eliminate excess glucose through urine, thereby reducing blood sugar. This mechanism also has beneficial effects on heart failure and kidney disease.

When used as an add-on medication for heart failure, empagliflozin helps to reduce the workload on the heart. It achieves this by lowering blood sugar levels and reducing the amount of fluid in the body, which in turn decreases the volume of blood that the heart has to pump. This reduction in workload can lead to improvements in symptoms of heart failure, such as breathlessness, fatigue, and swelling in the lower legs. Additionally, empagliflozin may lower the chances of the heart weakening further and reduce the risk of hospitalization due to heart failure.

Several studies have supported the use of empagliflozin as an add-on medication for heart failure. One double-blind, randomized, placebo-controlled trial found that empagliflozin, when added to standard therapy, resulted in a lower risk of cardiovascular death or hospitalization for heart failure. Over a median of 26.2 months, the empagliflozin group had a lower incidence of primary outcome events (13.8%) compared to the placebo group (17.1%). The total number of hospitalizations for heart failure was also lower in the empagliflozin group (407) compared to the placebo group (541).

Another study, a randomized, placebo-controlled crossover trial involving 20 patients with type 2 diabetes and chronic stable heart failure, examined the effects of empagliflozin 10 mg daily. The results showed a rapid increase in urinary glucose excretion within 3 hours of taking empagliflozin, indicating its effectiveness in removing excess glucose from the body. Additionally, empagliflozin led to a significant increase in the fractional excretion of sodium compared to the placebo, suggesting its diuretic properties.

Empagliflozin is generally safe and well-tolerated, but it is important to monitor for side effects and adjust dosages accordingly. Some common side effects include genital and urinary tract infections and hypotension. It is important for patients taking empagliflozin to inform their doctors and laboratory personnel, especially before any laboratory tests, as the medication can cause urine to test positive for glucose. Additionally, patients should be cautious about consuming foods with added sugar and alcohol, as these can affect blood sugar levels.

Explore related products

Wirkung von Empagliflozin und Colesevelam auf diabetische Dyslipidämie (German Edition)

$46

WIRKUNG VON EMPAGLIFLOZIN UND METFORMIN BEI DIABETISCHEN RATTEN (German Edition)

$62.93

Empagliflozin's impact on kidney function

Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. It is not used to treat type 1 diabetes, but it can help manage type 2 diabetes and improve health outcomes. Empagliflozin is also added to other heart failure medications to help control the condition.

Several studies have examined the effects of empagliflozin on kidney function in patients with chronic kidney disease (CKD) who are at risk of disease progression. The EMPA-KIDNEY trial, for example, randomly assigned 6609 participants to receive either empagliflozin (10 mg once daily) or a placebo. The primary outcome of the trial was to assess the progression of kidney disease, defined as end-stage kidney disease, a sustained decrease in estimated glomerular filtration rate (eGFR), or death from renal causes. During a median follow-up period of 2 years, the trial found that empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes compared to the placebo group.

Another study published in the New England Journal of Medicine examined the effects of empagliflozin in patients with CKD and an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m2 of body-surface area, or an eGFR of at least 45 but less than 90 ml per minute per 1.73 m2 with a urinary albumin-to-creatinine ratio of at least 200. This study also found that empagliflozin reduced the risk of kidney disease progression or cardiovascular death in patients at risk of CKD progression.

The exact mechanism of empagliflozin's protective effects on kidney function is not yet fully understood. Some studies suggest that it may be related to reducing pressure and swelling (inflammation) in the kidneys, as well as possible protective effects against glomerular hyperfiltration.

In summary, empagliflozin has been shown to reduce the risk of worsening kidney function in patients with heart failure and reduced ejection fraction (HFrEF). It also slows down the progression of CKD and reduces the need for dialysis or kidney transplantation, which can have significant impacts on quality of life and cardiovascular morbidity and mortality.

Safety considerations and potential side effects

Empagliflozin is a medication that belongs to a class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is used to manage blood sugar levels in individuals with diabetes, particularly those with type 2 diabetes mellitus. By acting as an SGLT2 inhibitor, empagliflozin helps the kidneys eliminate excess glucose through urine, thereby reducing blood sugar levels. This mechanism also reduces the workload on the heart and improves symptoms of heart failure, such as breathlessness, fatigue, and swelling in the lower legs. Additionally, empagliflozin can slow down the progression of chronic kidney disease by reducing pressure and inflammation in the kidneys.

When considering the addition of empagliflozin to a hospital formulary, it is essential to address the safety considerations and potential side effects associated with its use. Firstly, empagliflozin can cause a false positive for glucose in urine tests. Therefore, patients must inform their doctors and laboratory personnel that they are taking this medication before undergoing any laboratory tests. Wearing a diabetic identification bracelet is also recommended to ensure proper emergency treatment.

Furthermore, empagliflozin may interact with other medications and substances. Patients should disclose their use of prescription drugs, non-prescription medications, vitamins, nutritional supplements, and herbal products to their doctors and pharmacists. Alcohol consumption is another factor to consider, as it can increase the risk of low blood sugar levels. While drinking alcohol while taking empagliflozin is not prohibited, patients should follow the recommended guidelines and avoid drinking on an empty stomach.

Additionally, empagliflozin may be influenced by and have an impact on existing medical conditions. It is crucial for patients to inform their doctors if they have or have had urinary tract infections, problems with urination, low blood pressure, high cholesterol, pancreatic disease, yeast infections in the genital area, peripheral vascular disease, neuropathy, foot ulcers or sores, or kidney or liver disease. These disclosures can help doctors make informed decisions about prescribing empagliflozin and monitoring for potential side effects.

In the context of perioperative care, empagliflozin treatment should be temporarily interrupted, and ketone levels should be monitored closely. Patients who have undergone major surgery should not restart empagliflozin until their ketone levels have returned to normal, and their condition has stabilized. Additionally, patients who are acutely unwell, especially those experiencing vomiting, diarrhea, or fever, should also discontinue empagliflozin temporarily and follow the 'Sick day rules'.

Overall, empagliflozin is considered safe for long-term use, and there is no evidence that it harms general health. However, it is crucial to carefully manage this medication, especially in patients with existing medical conditions or those undergoing surgery, to ensure optimal safety and efficacy.

Drug interactions and contraindications

Empagliflozin is a medication used to manage and treat type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medication for diabetes. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. It is also used to treat chronic kidney disease and heart failure.

Empagliflozin may interact with other medications, including diuretics, ACE inhibitors, and angiotensin receptor blockers (ARBs). Co-administration with diuretics can increase urine volume and the frequency of voids, potentially leading to volume depletion. It may also cause symptomatic hypotension, especially in patients already taking diuretics, ACE inhibitors, or ARBs, as well as in the elderly, patients with renal impairment, and those with low systolic blood pressure. Empagliflozin increases serum creatinine and decreases eGFR, so renal function should be monitored. The medication is contraindicated when GFR is less than 30 mL/min/1.73m^2.

Empagliflozin is also associated with ketoacidosis, particularly in patients with type 1 diabetes, and those with predisposing factors such as pancreatic disorders, a history of pancreatitis, pancreatic surgery, or alcohol abuse. It is not recommended for use during pregnancy as there is limited data on its safety, although controlled studies in pregnant women have shown no evidence of fetal risk. It is also present in the milk of lactating rats, and due to the potential for adverse reactions in breastfed infants, it is not recommended while breastfeeding.

Additionally, patients taking empagliflozin should be cautious when consuming foods or drinks containing karela (bitter gourd or bitter melon) as it can lower blood sugar levels. Alcohol consumption can also increase the risk of low blood sugar levels, so it is recommended to stick to no more than 14 units per week and no more than 2 units per day.

It is important for patients taking empagliflozin to inform their doctor and laboratory personnel of their medication, especially before any laboratory tests, as the medication can cause urine to test positive for glucose.

Frequently asked questions